Biotech

All Articles

Zenas, MBX, Bicara head to Nasdaq in hot time for biotech IPOs

.It's an uncommonly active Friday for biotech IPOs, along with Zenas BioPharma, MBX and also Bicara ...

Atea's COVID antiviral neglects to halt hospital stays in stage 3

.Atea Pharmaceuticals' antiviral has stopped working an additional COVID-19 trial, but the biotech s...

Neurocrine's offer to spare mental illness prospect falls short

.Neurocrine Biosciences' mental illness course pivot has neglected. The biotech was not able to repl...

Sanofi pays out $110M upfront for late-stage radioligand therapy

.Sanofi has made an overdue access to the radioligand gathering, paying 100 thousand euros ($ 110 th...

F 2G brings up $100M for second effort to obtain new antifungal to market

.After F2G's very first attempt to acquire a brand-new lesson of antifungal to market was actually d...

Moderna targets $1.1 B in R&ampD investing cuts, drops 5 plans among earnings tensions

.Moderna has pledged to reduce R&ampD spending through $1.1 billion through 2027. The choice to shri...

Sanofi's $80M bank on Pivot dystrophy medicine ends in phase 3 fail

.Merely 4 months after Sanofi bet $80 million in upfront cash on Pivot Therapeutics' losmapimod, the...

Oncternal equity sinks 60% amid layoffs, trial terminations

.Cancer cells firm Oncternal Therapeutics is actually folding all its own scientific trials as well ...

Roche is carrying out hopes that its injectable being overweight prospect might ultimately illustrate 25% weight-loss in late-stage trial

.Roche is storing out hopes that its injectable weight problems possibility can ultimately display 2...

Novo Nordisk barrages 'outstanding' weight loss lead for dual-acting oral medicine in very early test

.Novo Nordisk has lifted the cover on a phase 1 test of its own oral amylin and also GLP-1 receptor ...